文献速递心律失常

中国心房颤动患者抗心律失常药物使用现状及安全性评估

[Current status of antiarrhythmic drug use and safety assessment in Chinese patients with atrial fibrillation].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2016-01-01

该研究纳入2011年1月至2013年12月共4008例接受抗心律失常药物治疗的心房颤动患者,随访24个月,记录处方药物、停药原因及不良反应。结果显示胺碘酮和普罗帕酮是最常用药物,但停药率较高,处方基本符合指南,缺乏更优抗心律失常药物仍是心房颤动药物治疗的主要问题。

要点

  • 胺碘酮处方占64.3%(2579例),普罗帕酮占31.1%(1247例),索他洛尔占3.7%(148例),莫雷西嗪占0.8%(34例)。
  • 胺碘酮组心力衰竭、冠心病和非缺血性心肌病患病率均显著高于普罗帕酮组。
  • 随访期间胺碘酮、普罗帕酮、索他洛尔和莫雷西嗪的停药率分别为28.8%、25.1%、14.2%和32.4%。

核心结论

  • 胺碘酮和普罗帕酮是中国心房颤动患者最常用的抗心律失常药物。
  • 抗心律失常药物处方基本符合心房颤动治疗指南。
  • 中国心房颤动患者抗心律失常药物停药率较高。
  • 缺乏更好的抗心律失常药物仍是心房颤动药物治疗的主要问题。

研究设计与样本

  • 研究纳入2011年1月至2013年12月共4008例接受抗心律失常药物治疗的心房颤动患者,随访24个月,记录处方药物、停药原因及不良反应。
  • 临床试验注册号:中国临床试验注册中心 ChiCTR-OCH-13003729。

主要发现

  • 胺碘酮处方占64.3%(2579例),普罗帕酮占31.1%(1247例),索他洛尔占3.7%(148例),莫雷西嗪占0.8%(34例)。
  • 胺碘酮组与普罗帕酮组比较:心力衰竭患病率4.0%(102/2579)vs 1.4%(17/1247),P<0.001;冠心病患病率13.5%(348/2579)vs 7.4%(93/1247),P<0.001;非缺血性心肌病患病率3.1%(78/2579)vs 0.7%(9/1247),P<0.001;胺碘酮组均显著高于普罗帕酮组。
  • 随访期间停药率:胺碘酮28.8%(743/2579),普罗帕酮25.1%(313/1247),索他洛尔14.2%(21/148),莫雷西嗪32.4%(11/34)。
  • 停用胺碘酮的原因:遵从医生决定75.7%(563例),无效3.0%(22例),不良反应4.3%(32例),患者自行决定17.0%(126例)。
  • 胺碘酮的不良反应包括甲状腺功能障碍56.3%(18例),心动过缓12.5%(4例),间质性肺炎/肺间质纤维化6.2%(2例),以及其他(胃肠道症状、皮疹、肝功能异常等)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the current status of antiarrhythmic drugs (AADs) use in Chinese patients with atrial fibrillation(AF) and assess the safety of AADs in this patient cohort. Methods: From January 2011 to December 2013, a total of 4 008 AF patients treated with AADs was enrolled in this study and patients were followed up for 24 months. Detailed information of prescribed drug, the causes of drug discontinuation and side effects were recorded. Results: Amiodarone was prescribed to 64.3%(2 579 cases) and propafenone to 31.1%(1 247 cases) of the enrolled patients, only 148 patients(3.7%) were treated with sotalol and 34 patients (0.8%) were treated with moracizine. The prevalence of heart failure (4.0%(102/2 579) vs. 1.4%(17/1 247, P<0.001), coronary heart disease (13.5% (348/2 579) vs. 7.4%(93/1 247), P<0.001) and non-ischemic cardiomyopathy (3.1%(78/2 579) vs. 0.7%(9/1 247), P<0.001) was significantly higher in patients treated with amiodarone than in the patients treated with propafenone. During the follow-up period, the discontinuation rate of amiodarone, propafenone, sotalol and moracizine was 28.8%(743/2 579), 25.1%(313/1 247), 14.2%(21/148) and 32.4%(11/34) respectively. The reasons of discontinuing amiodarone were: follow physicians' decision (75.7%, 563 cases), no effect (3.0%, 22 cases), side effects (4.3%, 32 cases) and patients' own decision (17.0%, 126 cases). The side effects of amiodarone included thyroid dysfunction (56.3%, 18 cases), bradycardia (12.5%, 4 cases), interstitial pneumonitis/pulmonary interstitial fibrosis (6.2%, 2 cases) and others (gastrointestinal symptom, rash, hepatic dysfunction, etc.). Conclusions: Amiodarone and propafenone are the most common AADs used in Chinese patients with atrial fibrillation. The prescription of AADs is essentially in accordance to the guideline of AF treatment. However, the discontinuation rates of AADs are high in Chinese AF patients. Lacking of better AADs is still a major problem in AF pharmacotherapy. Clinical Trial Registry Chinese Clinical Trial Registry, ChiCTR-OCH-13003729.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. He R, Du X, Liu SW, et al. [Current status of antiarrhythmic drug use and safety assessment in Chinese patients with atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016. PMID: 27903390. doi:10.3760/cma.j.issn.0253-3758.2016.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。